Medivir AB · OMXSTO:MVIR

Medivir AB — Kempen Life Sciences Conference, Immuno & Targeted Oncology Conference Day 2021

21 slides from Medivir AB's conference presentation, April 2021

  1. Slide 1: Kempen Life Sciences Conference

    KEMPEN LIFE SCIENCES CONFERENCE IMMUNO & TARGETED ONCOLOGY CONFERENCE DAY VIRTUAL APRIL, 2021

  2. Slide 2: Important notice

    Important notice You must read the following before continuing. The following applies to this document and the information provided in this presentation by Medivir AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in connection wit

  3. Slide 3: Table of content

    Table of content Slide 3

  4. Slide 4: Table of content

    Table of content 1. Executive summary 2. Birinapant deal 3. MIV-818 4. Other assets Slide 4

  5. Slide 5: Executive summary

    Executive summary Proprietary clinical asset Founded: 1988 • MIV-818 – A liver directed nucleotide prodrug Listed: Nasdaq OMX • In phase Ib clinical development Location: Stockholm Clinical collaboration and recent news Cash position: c. SEK 70M1) • Medivir and IGM Biosciences entered into an exclus

  6. Slide 6: Focused clinical program

    Focused clinical program Nucleotide prodrug Indication Preclinical Phase I Phase II Exclusivity MIV-818 Liver cancer IP : 2035 Partnered assets in clinical development Compound Mechanism Indication Phase I Phase II Partner Exclusivity Birinapant SMAC mimetic HNSCC2) IP : 2034 Multiple clinical progr

  7. Slide 7: Rights issue

    © 0f 5 & Se i, e es te 3! 2 ae ee ~~ sSe fh i i a. Rights issue

  8. Slide 8: Rights issue

    Rights issue • The preferential rights issue was completed successfully in February. Oversubscribed with 93.5 percent and Medivir received around MSEK 170 before transaction costs • The board of directors decided to exercise the overallotment option of MSEK 25 to specialist investor HealthInvest, wh

  9. Slide 9: Medivir has entered into exclusive licensing agreement with IGM biosciences for birinapant

    Medivir has entered into exclusive licensing agreement with IGM biosciences for birinapant Slide 9

  10. Slide 10: Licensing agreement with IGM Biosciences

    Licensing agreement with IGM Biosciences • IGM is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies • IGM received global development rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IA

  11. Slide 11: Licensing agreement with IGM Biosciences

    Licensing agreement with IGM Biosciences • Medivir will receive an upfront payment of USD 1 million upon signing the agreement, followed by an additional USD 1.5 million when birinapant is included by IGM in a clinical phase I study • Should birinapant be successfully developed and approved, Medivir

  12. Slide 12: IGM-8444 In Vivo Combination with Birinapant

    DR5: IGM-8444 In Vivo Combination with Birinapant Triple Negative Breast Cancer Model (MDA-MB-231) 1500 IGM-8444 Birinapant IGM-8444 + Birinapant Tumor volume (mm3) 1000 Vehicle 500 0 0 5 10 15 20 25 30 Days IGM-8444 (5 mg/kg Q2D x 11); Birinapant (2.5 mg/kg Q3D x 7) 12

  13. Slide 13: MIV-818 – for the treatment of liver cancer

    MIV-818 – for the treatment of liver cancer Slide 13

  14. Slide 14: MIV-818: A liver-directed nucleotide

    MIV-818: A liver-directed nucleotide • MIV-818 is an oral prodrug • Once absorbed from the GI-tract, MIV-818 is transported to the liver • The prodrug is taken up by liver cancer cells and converted into troxacitabine triphosphate (TRX-TP) • TRX-TP is incorporated into DNA and causes double-strand D

  15. Slide 15: MIV-818: Selective effect signal in liver cancer in phase Ia

    MIV-818: Selective effect signal in liver cancer in phase Ia • Clear signs of cell death, measured as DNA damage, observed in liver biopsies from tumor tissue in MIV-818 treated patients • The tumor selective effect is an early proof-of-concept of the intended liver-directed effect in patients Pre-d

  16. Slide 16: MIV-818: Clinical development plan in advanced liver cancer

    MIV-818: Clinical development plan in advanced liver cancer Phase Ib - Part A Part B Phase Ib monotherapy Combination therapy (n=up to 30) Potential (n=up to 30) Interpatient dose escalation follow-up Interpatient dose escalation 3+3 design 3+3 design 2020 2021 2022 Illustrative figure Slide 16

  17. Slide 17: Rapid market growth for HepatoCellular Carcinoma (HCC)

    Rapid market growth for HepatoCellular Carcinoma HCC) HCC: Combination therapies drive growth $5.3B  Liver cancer is the third most common cause of cancer-related deaths in the world  HCC is the most common form of liver cancer  New combination therapies (especially immuno-oncology combinations)

  18. Slide 18: Other assets

    e? ; ° Othernassets Sty

  19. Slide 19: Two clinical programs for partnering/out-licensing

    Two clinical programs for partnering/out-licensing Remetinostat – • Publication of final BCC data is being prepared • Investigator-initiated phase II trial in SCC was conducted at Stanford University. The study was terminated due to delays from Covid-19 resulting in drug shortage. We expect data fro

  20. Slide 20: Executive summary

    Executive summary Proprietary clinical asset • MIV-818 – A liver directed nucleotide prodrug Founded: 1988 Listed: Nasdaq OMX • In phase Ib clinical development Location: Stockholm Clinical collaboration and recent news Cash position: c. SEK 70M1) • Medivir and IGM Biosciences entered into an exclus

  21. Slide 21: Q/A

    Q/A Slide 21

Medivir — Kempen Life Sciences Conference, Immuno & Targeted Oncology Conference Day 2021 on 6ix